Literature DB >> 2071147

D11S146 and BCL1 are physically linked but can be discriminated by their amplification status in human breast cancer.

P Szepetowski1, C Nguyen, D Perucca-Lostanlen, G F Carle, Y Tsujimoto, D Birnbaum, C Theillet, P Gaudray.   

Abstract

Band q13 of chromosome 11 is frequently altered in a number of human cancers. We have undertaken physical mapping in this region, starting with D11S146, an anonymous 11q13 DNA fragment. This probe has been used by others as a landmark to locate MEN1, a locus of predisposition to multiple endocrine neoplasia. Long-range restriction mapping locates D11S146 within approximately 400 kb of the BCL1 translocation breakpoint involved in certain B-cell malignancies. BCL1 and two proto-oncogenes, INT2 and HST, were previously found to be coamplified in approximately 1/5 breast carcinomas. Although close to BCL1, D11S146 is present in less than 3/4 of these amplification units and delimits their centromeric boundary. Therefore, we propose that D11S146 defines two genetic regions. The centromeric region--PYGM/D11S146--contains MEN1. The telomeric one includes the D11S146/BCL1/INT2/HST area and is relevant to DNA amplification in carcinomas and to B-cell translocations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2071147     DOI: 10.1016/0888-7543(91)90326-a

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  3 in total

1.  New gene in the homologous human 11q13-q14 and mouse 7F chromosomal regions.

Authors:  V Ollendorff; P Szepetowski; M G Mattei; P Gaudray; D Birnbaum
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

Review 2.  Chromosome 11q13 markers and D-type cyclins in breast cancer.

Authors:  G Peters; V Fantl; R Smith; S Brookes; C Dickson
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

3.  Oesophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1.

Authors:  J Adélaide; G Monges; C Dérdérian; J F Seitz; D Birnbaum
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.